Nab-Paclitaxel Combined With Local Therapy in Relapsed SCLC

Conditions

• Extensive Stage Small Cell Lung Cancer (ES-SCLC)
• Small Cell Lung Cancer

Eligibility Criteria

Sex

ALL

Age

18 Years - 75 Years

Healthy Volunteers

Not accepted

Interventions

• Albumin-bound Paclitaxel Combined with Local Therapy — RADIATION
  The treatment period consisted of 6 cycles of albumin-bound paclitaxel at a dose of 260 mg/m² via IV infusion on a Q3W schedule. (Optional) Concurrent or sequential local therapy was administered until disease progression or unacceptable toxicities. Local therapy regimen: * Radiation timing: Radiotherapy could be administered concurrently or sequentially with albumin-bound paclitaxel, determined by the radiation oncologist based on the patient's performance status (PS), tumor burden/location, chemotherapy tolerance, bone marrow reserve (neutrophil/platelet counts), and risk of acute radiation toxicity (e.g., CNS, GI tract). * Radiation fields: Target fields must cover at least 1 pathologically/ radiologically confirmed progressive lesion, prioritizing: ① Intrapulmonary primary lesion + ipsilateral hilar/mediastinal lymph node metastases (if residual/progressive); ② Symptomatic metastases; ③ Lesions at risk of severe complications. Excessive irradiation to normal tissues was strictly pr
• Albumin-Bound Paclitaxel /nab-Paclitaxel — DRUG
  The treatment period consisted of 6 cycles of albumin-bound paclitaxel at a dose of 260 mg/m² via IV infusion on a Q3W schedule. (Optional) Concurrent or sequential local therapy was administered until disease progression or unacceptable toxicities.

Study Details

This is a prospective, single-arm, investigator-initiated clinical study (IIT) designed to evaluate the efficacy and safety of nab-paclitaxel combined with local radiotherapy for patients with extensive-stage small cell lung cancer (ES-SCLC) whose disease has progressed after first-line treatment. Small cell lung cancer (SCLC) is an aggressive type of lung cancer, and extensive-stage SCLC (ES-SCLC) refers to its advanced stage. For patients whose cancer progresses after first-line treatment, there are very limited effective second-line and later-line treatment options. Commonly used clinical regimens such as topotecan and lurbinectedin only provide modest improvements in tumor response and survival, and often cause severe hematological toxicities (represented by bone marrow suppression). This leaves patients in a persistent dilemma of "insufficient efficacy and limited tolerability", highlighting a clear unmet medical need for better treatment options in this population. Against this background, this study explores a comprehensive treatment strategy using nab-paclitaxel as the chemotherapy backbone, combined with local radiotherapy in eligible patients. Nab-paclitaxel is a nanoparticle albumin-bound form of paclitaxel, with a relatively controllable toxicity profile and manageable administration in clinical practice. Local radiotherapy may create a synergistic effect by improving the tumor immune microenvironment and enhancing local tumor control, with the goal of providing better evidence for a "chemotherapy ± local therapy" combination as a second-line treatment option.

Key Dates

First listed

Apr 23, 2026

Start date

Apr 6, 2026

Status verified

Jan 2026

Primary completion

Jan 1, 2028

Completion

Dec 31, 2030

Study Design

Enrollment

84 participants (estimated)

Allocation

NA

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Arms

• Other: Albumin-bound Paclitaxel Combined with Local Therapy
  The treatment period consisted of 6 cycles of albumin-bound paclitaxel at a dose of 260 mg/m² via IV infusion on a Q3W schedule. (Optional) Concurrent or sequential local therapy was administered until disease progression or unacceptable toxicities. Local therapy regimen: * Radiation timing: Radiotherapy could be administered concurrently or sequentially with albumin-bound paclitaxel, determined by the radiation oncologist based on the patient's performance status (PS), tumor burden/location, chemotherapy tolerance, bone marrow reserve (neutrophil/platelet counts), and risk of acute radiation toxicity (e.g., CNS, GI tract). * Radiation fields: Target fields must cover at least 1 pathologically/ radiologically confirmed progressive lesion, prioritizing: ① Intrapulmonary primary lesion + ipsilateral hilar/mediastinal lymph node metastases (if residual/progressive); ② Symptomatic metastases; ③ Lesions at risk of severe complications. Excessive irradiation to normal tissues was strictly p

Primary Outcome Measure

Progression-Free Survival (PFS) [ Time Frame: up to 30 months ]

Central Contacts

• Peng Zhang DR.
  +8615221538837
  [email protected]

Find similar trials

Related Studies

• Tissue Procurement and Natural History Study of People With Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Extrapulmonary Small Cell Cancer, Pulmonary Neuroendocrine Tumors, and Thymic Epithelial Tumors
  Recruiting · National Cancer Institute (NCI) · Bethesda, Maryland
• PET/CT Imaging of Small Cell Lung Cancer Using 89Zr-DFO-SC16.56
  PHASE1/PHASE2 · Recruiting · Memorial Sloan Kettering Cancer Center · New York, New York
• The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
  PHASE1/PHASE2 · Recruiting · PMV Pharmaceuticals, Inc · La Jolla, California
• Tempus Small Cell Lung Cancer Observational Study (Sculptor)
  Recruiting · Tempus AI · Aurora, Colorado